The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...

For decades, one of the world’s most contagious diseases was considered eradicated in the U.S. But now measles is roaring back.

NPR's Pien Huang speaks with pediatrician Alexandra Cvijanovich and Professor Jason L. Schwartz about trying to shore up trust about vaccines.

Professor Hirohide Saito and his research team have developed a new microRNA-responsive hybrid mRNA switch, enabling precise, ...

When the COVID-19 pandemic swept across the world in 2020, the mRNA vaccines came to the rescue of many people—but in the ...

The elephant vaccine closely resembles other mRNA vaccines made for humans. mRNA packed in lipid nanoparticles carries ...

The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

The author says the action creates mistrust of the committee’s vaccine recommendations and further increases patients’ and ...

The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...